Visiongain predicts that the world RNAi therapies market will reach $391m in 2018

LONDON - Sept. 10, 2015 - PRLog -- The world RNAi therapies market will reach $391m in 2018 predicts new visiongain report

A new report by visiongain predicts that the world RNAi therapies market will reach $391m in 2018. This forecast and others appear in RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025, published in June 2015. Visiongain is a business information provider based in London, UK.

RNA interference is a biological process that allows the silencing of gene expression –potentially allowing the treatment of a wide range of diseases such as cancers, infections and genetic disorders. Since the discovery of RNAi in 1998, the field of RNAi therapeutics has experienced cycles of increasing and declining interest from Big Pharma companies, attracted by the prospect of developing treatments for difficult-to-treat diseases, but stymied by barriers to RNAi delivery into tissues and late-stage pipeline failures. In 2015, optimism around RNAi therapies is again building as biotechs develop innovative delivery technologies and demonstrate clinical proof-of-concept. Visiongain’s report finds that the first RNAi-based therapies could reach the market as early as 2018, with rapid growth expected during the forecast period of the report.

Thomas Ling, a senior pharmaceutical and medical devices industry analyst and consultant in visiongain, said: “Rapid growth in revenues from RNAi therapies will be driven by a pipeline of over 70 therapies targeting more than 50 different genes, proteins or viral or bacterial genomes. Therapies for genetic diseases, cancer, and infectious diseases such as hepatitis B and C are currently in late-stage development. Although some Big Pharma companies have exited the RNAi space in recent years, RNAi therapy developers are reporting increased interest in partnership opportunities, and a few Big Pharma players have re-entered the field, most notably Roche with its acquisition of Santaris Pharma in 2014.”

Visiongain’s report provides revenue forecasts to 2025 for the world RNAi therapies market and leading pipeline candidates. The report discusses selected leading pipeline therapies from a pipeline of more than 70 unique therapies in development by more than 15 biotech companies including Alnylam, Arrowhead Research, Gradalis Incorporated, Quark Pharmaceuticals, Roche, RXi Pharmaceuticals, Silence Therapeutics, Silenseed, Sylentis and Tekmira. Visiongain’s report also discusses key therapeutic areas for RNAi therapies, commercial news, and analysis of strengths, weaknesses, opportunities and threats. It includes interviews with industry experts regarding current market trends. The report also includes a STEP analysis, providing insight into the social, technological, economic and political factors affecting this market.

RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 Prospects for siRNAs, shRNAs and ddRNAi Approaches adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.